HS-20117 clinical trials
Also written HS-20117 and PM1080.
How each study uses HS-20117 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HS-20117 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
CAPOX Regimen (1) · Xelox (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1) · Modified FOLFOX6 Regimen (1)
Studies
Open first, then newest update. How each study uses HS-20117 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 2/3Hansoh BioMedical R&D CompanyNCT06417008Written as HS-20117
- Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid TumorsRecruitingPhase 1Hansoh BioMedical R&D CompanyNCT06621563Written as HS-20117+CAPEOX
- A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid TumorsNot yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT05940116Written as HS-20117
Given beside what is tested · 2 — HS-20117 is usual care or a partner of the new treatment
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07414953Written as HS-20117
- A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT06963502Written as HS-20117